Login

Nadezda Kolosa

ORCID: 0000-0002-5707-3580
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5023135428
Research Areas
  • Asthma and respiratory diseases
  • Respiratory and Cough-Related Research
  • Inhalation and Respiratory Drug Delivery
  • Tracheal and airway disorders
  • Pneumonia and Respiratory Infections
  • Respiratory viral infections research

Daugavpils University
 2019

 Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial
OPENALEX - Publications 
Steve Cunningham Pedro A. Piedra Federico Martinón‐Torres Henryk Szymański Benedicte Brackeva and 59 more Evelyne Dombrecht Laurent Detalle C. Fleurinck Steve Cunningham Pedra A Piedra Stijn Verhulst Inge Matthijs Marijke Proesmans Tessa Goetghebuer Miroslava Bosheva S Dosev Olga Nikolova Petranka Chakarova Elba Wu Hupat Juan Mesa Monsalve Mirjana Turkalj Natasa Mesaric Antoncic Goran Tešović Mirna Sipl Blaženka Kljaić Bukvić Irena Ivković‐Jureković Biserka Čičak Sylva Skálová Gerd Horneff Christian Vogelberg E Gács Krisztina Kalocsai A. Madarasi Lajos Kovács Zoltán Novàk Zsolt Bene Shai Ashkenazi Aviv Goldbart Lea Bentur Nadezda Kolosa Dace Gardovska Poh Guan Khaw Teck Hock Toh Jessie Anne de Bruyne Kah Kee Tan Edison Alberto Junior Sablan Benjamin Anjanette De Leon Henryk Szymański Miroslav Repko K. Kralinský Ignacio Salamanca de la Cueva Carlos Rodrigo Federico Martinón‐Torres María Pilar Cedena Romero Emilio Monteagudo Montesinos Jamaree Teeratakulpisarn Thanyawee Puthanakit Peninnah Oberdorfer Boonyarat Warachit Benedicte Brackeva Evelyne Dombrecht Laurent Detalle C. Fleurinck

10.1016/s2213-2600(20)30320-9 article EN The Lancet Respiratory Medicine 2020-09-28
 Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings
OPENALEX - Publications 
Oliver Kornmann János Mucsi Nadezda Kolosa Lorraine Bandelli Biswajit Sen and 2 more Lisa C. Satlin Peter D’Andrea

10.1016/j.rmed.2019.105809 article EN publisher-specific-oa Respiratory Medicine 2019-11-14
 P223 Once-daily low-dose indacaterol/mometasone via breezhaler® reduces exacerbations in patients with inadequately controlled asthma: phase III QUARTZ study
OPENALEX - Publications 
Oliver Kornmann János Mucsi Nadezda Kolosa Lorraine Bandelli LC Satlin and 2 more Biswajit Sen Peter D’Andrea

<h3>Introduction</h3> GINA 2019 recommends LABA/ICS as preferred controller therapy in patients with inadequately controlled asthma despite low-dose ICS treatment. This Phase-III study (NCT02892344; the QUARTZ Study) is part of PLATINUM clinical program which supports development both indacaterol acetate/mometasone furoate (IND/MF) and acetate, glycopyrronium bromide mometasone (IND/GLY/MF). Specifically, we evaluated efficacy safety IND/MF 150/80 µg once daily (o.d.) via...

10.1136/thorax-2019-btsabstracts2019.366 article EN 2019-11-12
Coming Soon ...